Want to invest in artificial intelligence (AI), cloud computing, digital media, and e-commerce in one fell swoop? You could ...

Vertex Pharmaceuticals unveiled impressive long-term results for its CRISPR/Cas9 gene therapy, PrCASGEVY, at the EHA Congress ...

Vertex Pharmaceuticals (NasdaqGS:VRTX) recently received approval from the European Commission for ALYFTREK, enhancing its reach in European markets with new reimbursement agreements in Ireland and ...

VRTX secures EU approval for Alyftrek, a next-in-class triple combination regimen for treating people with CF aged six years ...

Vertex Pharmaceuticals (VRTX) reached $452.16 at the closing of the latest trading day, reflecting a +1.56% change compared to its last close.

Vertex Pharmaceuticals secured EU approval for ALYFTREK, a next-gen cystic fibrosis therapy boasting a better efficacy ...

Vertex Pharmaceuticals today announced that the European Commission has granted approval for Alyftrek ...

The success of Vertex's opioid alternative Journavx could aid a group of biotechs that aim to take a similar path with NaV1.8 ...

Vertex Pharmaceuticals said on Tuesday its next-generation cystic fibrosis treatment has won European Union approval for a ...

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for ALYFTREK ® (deutivacaftor/tezacaftor/vanzacaftor) for the treatment of people with cystic ...

Buying $100 In VRTX: If an investor had bought $100 of VRTX stock 10 years ago, it would be worth $345.57 today based on a price of $445.20 for VRTX at the time of writing.